UAB Phase I Clinical Trials Program – Phase I Hematologic Malignancy Trials

Hematologic Malignancies

AML
- CD33 positive
- Treatment Naive

UAB 1323
- SGN33A-001

Monotherapy cohort
- IV SGN-CD33A q21-day cycle
- Combination cohort
- q28-day cycle

SPECIAL INSTRUCTIONS:
- Cohorts Open:
  - HMA Combo
  - SGN-CD33A + Azacitidine
  - SGN-CD33A + Decitabine
  - Treatment Naive
  - APL
  - NPM1 mutated (FLT-3 wildtype)

AML
- Known p53WT
- Failed all therapy

UAB 1383
- MDM2 Inhibitor

Arm 1: PO AMG 232 -7 days on/7 days off
Arm 2: PO AMG 232 -7 days on/7 days off plus trametinib daily dose

SPECIAL INSTRUCTIONS:

NHL/HL
- Any except Burkitt’s
- Failed ≥ 1 therapy

UAB1318
- PI3K + JAK

Monotherapy Expansion:
- INCB040093 PO- QD in 21 day cycles,
- Combination Expansion:
- INCB039110 with INCBO40093 PO QD 21 days
  
SPECIAL INSTRUCTIONS:

NHL
- MCL, DLBCL*
- Failed ≥ 2 therapy

UAB1505
- SGN-CD70A

SGN-CD70A IV on
Day 1 - q 21 day cycle

SPECIAL INSTRUCTIONS:

NHL/HL
- Any except Burkitt’s
- Failed ≥ 1 therapy

UAB1481
- PI3K Inhibitor

INCB050465 PO -QD or BID regimen continuous, 21 day cycle

SPECIAL INSTRUCTIONS:

FOR REFERRALS OR QUESTIONS CALL (24/7): 205-996-HOPE (996-4673) OR EMAIL: phase1referral@uab.edu

Version 9-18-2015